Li Qiang, director of the respiratory and critical care medicine department at the hospital, said the patient had over 10 ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

Healthcare stock Theralase Technologies (TSXV:TLT) recently discovered that its lead drug candidate, Ruvidar, has the potential to inhibit deubiquitinating enzymes, which are linked to certain cancers ...

Radiation from the images causes 5 percent of cancer cases, according to a new study. The doctor who made this grim discovery ...